Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 142Breast Neoplasms 97Lung Neoplasms 72Brain Neoplasms 67Glioblastoma 59Carcinoma, Non-Small-Cell Lung 54Glioma 52Pancreatic Neoplasms 39Neoplasms 39Neoplasm Metastasis 36Colorectal Neoplasms 31Carcinoma, Hepatocellular 30Lymphoma, Large B-Cell, Diffuse 27Carcinoma, Renal Cell 27Multiple Myeloma 26Squamous Cell Carcinoma of Head and Neck 25Rectal Neoplasms 21Melanoma 21Ovarian Neoplasms 20Astrocytoma 20Urinary Bladder Neoplasms 18Lymphoma, Follicular 18Uterine Cervical Neoplasms 17Colonic Neoplasms 17Head and Neck Neoplasms 16Lymphoma 15Esophageal Neoplasms 15Sarcoma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 14

Interventions

Mitotane 7Cisplatin 6pembrolizumab 5Etoposide 3Doxorubicin 3camrelizumab 2apatinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Cytoreduction Surgical Procedures 2sodium thiosulfate 1iodophenyl metomidate 1fludarabine phosphate 1dostarlimab 1cemiplimab 1cabozantinib 1cabazitaxel 1antineoplaston AS 2-1 1antineoplaston A10 1Suramin 1Sunitinib 1Streptozocin 1Sorafenib 1Radiation 1Paclitaxel 1Observation 1Nivolumab 1Megestrol Acetate 1Lymph Node Excision 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Adrenocortical Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡